The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact The Gross Law Firm
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN d...
Regeneron Is Playing Defense With Capital Allocation
Regeneron has started 2025 with an increase in defensive capital allocation - initiation of a dividend and an expanded share buyback program. Increased competitive pressure on the Eylea franchise i...
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman
SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing leg...
Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings
Regeneron reported Q4 earnings on Tuesday, with revenues up 10% versus Q4 in 2023. EYLEA HD has stabilized its franchise with a modest sales growth of 1% in 2024 versus 2023. Biosimilar competitio...
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit - Hagens Berman
REGN Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2025 / Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is facing mounting pressure on multi...
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). S...
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the...
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sen...
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights – REGN
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
ROSEN, NATIONALLY RECOGNIZED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in ...
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) betwee...
Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fe...
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fe...
Related Companies